Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

This study is looking for adults aged 18 or older who have been diagnosed with advanced non-small cell lung cancer that has spread to other parts of the body (Stage IV). Importantly, you should not have received any previous treatment for this advanced lung cancer. Doctors will also check that your cancer doesn't have certain genetic changes (like EGFR, ALK, ROS1, NTRK, BRAF, or RET mutations) that would mean a different standard treatment is available for you.

You should generally be in good health for someone with a cancer diagnosis, meaning you're able to carry out most daily activities without too much difficulty. Your doctors will also need to confirm that your body's organs, like your kidneys and liver, are working well enough to safely take part.

There are also some reasons why you might not be able to join. For example, if you've had a type of lung cancer called small-cell lung cancer mixed with non-small cell, or if you've recently had another type of cancer. Also, if you've previously received certain types of immunotherapy medicines, or if you have an active autoimmune disease that requires ongoing treatment, you wouldn't be able to participate. Pregnant or breastfeeding individuals cannot join either.

If you decide to take part in this study, the doctors and nurses will explain everything in detail. You would receive one of the two treatment combinations (either Zimberelimab and Domvanalimab with chemotherapy, or Pembrolizumab with chemotherapy). These medicines are typically given through a drip (intravenously) at scheduled visits to the hospital or clinic. The specific chemotherapy drugs used might include Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, or Pemetrexed.

Throughout the study, you would have regular appointments for check-ups, blood tests, and scans to monitor how you are doing and how the treatment is working. The study team would carefully watch for any side effects and manage them. The total duration of your participation would depend on how your body responds to the treatment, but these types of studies typically involve ongoing treatment and follow-up for a significant period. You would continue to receive treatment for as long as it is helping you and you are tolerating it well.